(Total Views: 538)
Posted On: 09/14/2020 12:29:39 PM
Post# of 154115
Re: nmbr1stckpckr #55721
I cant speak for the other greedy mfers, but for me there are two primary issues with a buyout.
The first is that it creates the possibility that the acquiring company doesnt release Leronlimab for some or all indications. I do not want this drug to be shelved.
The second is that a buyout, by definition is a discounted price due to the elimination of risk.
With that said I would entertain buyout offers if it was a reasonable price and with a company that doesnt have competing products that would encourage them to shelve it.
The first is that it creates the possibility that the acquiring company doesnt release Leronlimab for some or all indications. I do not want this drug to be shelved.
The second is that a buyout, by definition is a discounted price due to the elimination of risk.
With that said I would entertain buyout offers if it was a reasonable price and with a company that doesnt have competing products that would encourage them to shelve it.
(6)
(0)
